AMDL - 500 Beiträge pro Seite

[Dezi]

Gibt es noch Aktionäre von AMDL, die wissen, ob und was bei dem Unternehmen noch (was) läuft. Oder ist das eine Investitionsruine ohne Zukunft?

[Nedle25]

bin hier auch investiert!
keine ahnung!?

[bukstar]

AMDL, Inc., Retains Trent & Company
Sunday March 20, 10:00 am ET

TUSTIN, Calif., March 20 /PRNewswire/ -- AMDL, Inc. (Amex: ADL - News), a developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that it has retained Trent & Company, as its public relations counsel.

ADVERTISEMENT
Gary L. Dreher, president and CEO of AMDL, Inc., said, "We are pleased that Trent & Company will be helping us communicate, inform and educate the medical and patient community and news media regarding the Company`s proprietary products."

AMDL recently announced that its consultant, Diagnostic Oncology Clinical Research Organization (DOCRO), had submitted to the U.S. Food and Drug Administration, on behalf of AMDL, additional data in connection with the new application for 510(k) clearance to market AMDL`s DR-70® test in conjunction with CEA as an aid in monitoring patients previously diagnosed with progressing colorectal cancer.

Specifically, DOCRO submitted data showing that by using DR-70® in conjunction with the CEA test, which is the standard test for this disease, there is a significant positive gain in sensitivity of 24% for monitoring the progression of the clinical disease status in previously diagnosed colorectal cancer patients as compared to using the CEA test by itself. The CEA (carcinoembryonic antigen) test has sensitivity that varies from 40 to 70 percent, according to published literature.

"We are so pleased to be working with AMDL on this significant medical advancement," said Nancy Trent, the president of Trent & Company. "Monitoring colon cancer is crucial during treatment and remission, and DR-70 provides patients with an accurate way to monitor the disease."

About AMDL

AMDL, Inc. (Amex: ADL - News), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70® non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70® was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70® have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70® can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body`s immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com .

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company`s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company`s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


Source: Trent & Company

[bukstar]

AMDL Reports Fiscal 2004 Financial Results
Wednesday March 30, 10:00 pm ET

TUSTIN, Calif., March 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL - News), developer and marketer of tests for the early detection of cancer and other serious diseases, today reported its fiscal 2004 financial results.

ADVERTISEMENT
AMDL`s revenues from its DR-70® test kit increased to $62,717 compared to $43,828 for the year ended December 31, 2003, an increase of 43.1%. OEM revenues decreased to $123,465 compared to $316,279 for the prior year period, a decrease of 61.0%. Total product revenues for the year ended December 31, 2004 totaled $186,182, a 48.3% decrease compared to product revenues of $360,107 for the year ended December 31, 2003. Net loss for fiscal 2004 was $2.6 million or ($0.12) per share compared to a net loss of $2.9 million, or ($0.23) per share, for the year ended December 31, 2003.

"The Company`s primary objective remains receiving U.S. Food and Drug Administration clearance to market its DR-70® test in the U.S. FDA approval would simultaneously increase market awareness and acceptance in international markets," Gary L. Dreher, CEO of AMDL, said. AMDL recently announced that its consultant, Diagnostic Oncology Clinical Research Organization (DOCRO), had submitted to the U.S. Food and Drug Administration, on behalf of AMDL, additional data in connection with the new application for 510(k) clearance to market AMDL`s DR-70® test in conjunction with CEA (carcinoembryonic antigen) as an aid in monitoring patients previously diagnosed with progressing colorectal cancer. Specifically, DOCRO submitted data showing that by using DR-70® in conjunction with the CEA test, which is the standard test for this disease, there is a significant positive gain in sensitivity of 24% for monitoring the progression of the clinical disease status in previously diagnosed colorectal cancer patients as compared to using the CEA test by itself. The CEA test has sensitivity that varies from 40 to 70 percent, according to published literature. AMDL is awaiting a response from the FDA.

About AMDL

AMDL, Inc. (Amex: ADL - News), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70® non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70® was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70® have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70® can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body`s immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com.

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company`s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company`s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.